A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening
A Phase I Study of the In Vivo CAR-T Platform for Treating Advanced Malignant Tumors Based on Target Screening
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
50 participants
Nov 21, 2025
INTERVENTIONAL
Conditions
Summary
This is a single-arm, open-label, single-center, dose-escalation Phase I platform study designed to evaluate the safety, tolerability, preliminary efficacy, pharmacokinetics, and pharmacodynamics of an in vivo CAR-T therapy (V001 Injection, targeting BCMA, GPRC5D, DLL3,FcRH5, etc.) in patients with advanced malignant tumors.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
An in vivo CAR-T drug targeting BCMA administered intravenously
An in vivo CAR-T drug targeting GPRC5D administered intravenously
An in vivo CAR-T drug targeting DLL3 administered intravenously
An in vivo CAR-T drug targeting FcRH5 administered intravenously
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07395479